EXPLORING MARINE ORGANISMS AS POTENTIAL SOURCES OF BIOACTIVE COMPOUNDS FOR PHARMACEUTICAL APPLICATIONS
Commentary - (2023) Volume 12, Issue 3
Department of Biotechnology, Vilnius University,
Author info »
Exploring marine organisms for bioactive compounds is a promising area of
research within pharmacognosy. The diverse and largely unexplored marine
environment holds immense potential for discovering novel compounds with
pharmaceutical applications. Marine organisms, including various species
of algae, sponges, corals, molluscs, and even some microorganisms, have
been found to produce a wide range of bioactive compounds with potential
pharmaceutical, medical, and biotechnological applications. The oceans are
home to a vast array of organisms, including sponges, corals, algae, molluscs,
and many others. Each of these species may possess unique bioactive
compounds. Researchers often embark on expeditions to collect samples
from different marine habitats, including deep-sea environments, coral reefs,
and coastal areas.
Sponges are particularly rich sources of bioactive compounds. Compounds
like spongin, alkaloids, and terpenes have been isolated from various sponge
species. Coral reefs are incredibly diverse ecosystems and are known to harbour
a wide range of bioactive compounds, including alkaloids, peptides, and
terpenoids. Many marine organisms have symbiotic relationships with microorganisms.
These symbionts can be a source of unique bioactive compounds.
Various marine animals, such as cone snails, sea anemones, and fish, produce
peptides with potent pharmacological activities, including analgesics
and neurotoxins. Compounds derived from marine organisms have shown
promise as potential anti-cancer agents. Examples include compounds from
sea cucumbers and marine microorganisms.
Marine organisms have yielded compounds with significant antimicrobial
properties, which could be crucial in the fight against antibiotic-resistant
bacteria. Some marine-derived compounds have shown anti-inflammatory
effects, which could be valuable in treating inflammatory conditions. Compounds
with neuroprotective properties, potentially beneficial for neurodegenerative
diseases, have been identified in certain marine species. Techniques
such as bioprospecting, metagenomics, and genetic engineering are being
used to optimize the discovery and production of bioactive compounds from
marine organisms. It’s crucial to consider sustainable harvesting practices
and conservation efforts to ensure the long-term viability of marine resources
for pharmaceutical applications.
Research is being conducted to develop effective formulations and delivery
systems for bioactive compounds derived from marine sources. Researchers
in this field must also address regulatory and ethical issues related to the
collection and utilization of marine organisms for pharmaceutical purposes.
Overall, the exploration of marine organisms for bioactive compounds offers
a rich and untapped source of potential pharmaceutical agents, with applications
in various fields of medicine. However, it’s essential to approach this
research with a commitment to environmental sustainability and ethical considerations.
Utilizing bioinformatics tools and metagenomic approaches to
analyze the genetic potential of marine microbiomes for bioactive compound
Cytarabine (Cytosar-U) which is originally isolated from a Caribbean sponge,
Cytarabine is a crucial chemotherapy drug used in the treatment of leukemia
and lymphoma. Eribulin (Halaven) is derived from the sea sponge Halichondria
okadai, Eribulin is used to treat metastatic breast cancer. Brentuximab
vedotin (Adcetris) utilizes a synthetic version of dolastatin 10, originally derived
from a marine mollusc, for the treatment of certain lymphomas.
It’s important to note that while marine organisms offer a vast potential for the
discovery of bioactive compounds, ethical and sustainable practices should
be employed to protect marine ecosystems. Additionally, thorough research
and clinical trials are necessary to validate the safety and efficacy of any compounds
derived from marine sources for pharmaceutical applications.
The authors are very thankful and honoured to publish this article in the respective
Journal and are also very great full to the reviewers for their positive
response to this article publication.
Conflict Of Interest
We have no conflict of interests to disclose and the manuscript has been read
and approved by all named authors.
Department of Biotechnology, Vilnius University, Lithuania
Received: 29-Aug-2023, Manuscript No. mjpms-23-117138;
, Pre QC No. mjpms-23-117138(PQ);
Editor assigned: 31-Aug-2023, Pre QC No. mjpms-23-117138(PQ);
Reviewed: 14-Sep-2023, QC No. mjpms-23-117138;
Revised: 19-Sep-2023, Manuscript No. mjpms-23-117138(R);
26-Sep-2023, DOI: 10.4303/2320-3315/236052
Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.